http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16
-
Gilead Sciences to Present at the Baird 2015 Healthcare Conference on Wednesday, September 9
-
Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study
-
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
-
European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment
-
Wall St higher ahead of Fed meeting
-
Pre-Open Stock Movers 07/29: (CYT) (RUBI) (BWLD) Higher; (YELP) (DATA) (TWTR) Lower (more...)
-
After-Hours Stock Movers 07/28: (RUBI) (BWLD) (CTXS) Higher; (YELP) (AKAM) (TWTR) Lower (more...)
-
Gilead Sciences Announces Third Quarter 2015 Dividend
-
Wall Street bounces back after five-day selloff
-
Gilead Announces Executive Promotions
-
Trading Radar for 7/28: Ford (F), Twitter (TWTR) DuPont (DD), Pfizer (PFE), UPS (UPS), US Steel (X) Report
-
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
-
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide
-
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
-
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)
-
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9
-
Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia
-
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
-
Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
-
Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
-
Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13
-
Gilead Sciences Acquires EpiTherapeutics
-
Gilead Sciences Declares First Quarterly Cash Dividend
-
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
-
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015
-
Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease
-
Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C
-
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment
-
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C
-
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11
-
Streetinsider.com's Hot Lunchtime Reads 10/31: (LNKD) (GILD) (TWTR) (TSLA)
-
Gilead Sciences's (GILD) Harvoni RX 445 in Week One
-
UPDATE: Gilead Sciences (GILD) Hits Session Lows
-
Gilead Sciences (GILD): Traders Discuss Cheaper Version of Sovaldi
-
Griffin's Blue Ridge Capital Shows New Stakes in Allegion (ALLE), Castlight Health (CSLT), Myriad Genetics (MYGN), Walgreen (WAG) (more...)
-
Stocks Choppy With Escalation of Ukraine Violence
-
Stocks Sink; Margin Fears Take Center Stage
-
Blood-Bath in Nasdaq Stocks
-
Did Gilead (GILD) and Waxman Plan Meeting Ahead of Letter?
-
Stocks Weaker, Led by High-Beta Names
-
Blue Ridge Capital Enters Apple (AAPL), Twitter (TWTR) (more...)
-
Notable Analyst Rating Changes 01/08: (RAD) (PNRA) (FLIR) Upgraded; (AMBA) (TWTR) (TCS) Downgraded
-
Streetinsider.com's Hot Lunchtime Reads 12/02: (TWTR) (AMZN) (GILD) (TSLA)

